The tables in this section are audited by the external auditor.
The following table shows the equity of the individual members of the Board of Directors and persons closely linked to them.
31.03.2024 | 31.03.2023 | |||||||||||||||
Total Shares | of which Restricted Shares 1) | RSUs | Options | Total Shares | of which Restricted Shares 2) | RSUs | Options | |||||||||
Robert F. Spoerry, Chair | 59,539 | 9,432 | 58,214 | 10,812 | ||||||||||||
Stacy Enxing Seng, Vice-Chair | 10,321 | 3,129 | 9,748 | 3,652 | ||||||||||||
Gregory Behar, Member | 1,737 | 1,737 | 1,164 | 1,164 | ||||||||||||
Lynn Dorsey Bleil, Member | 7,120 | 3,129 | 6,547 | 3,652 | ||||||||||||
Lukas Braunschweiler, Member | 18,415 | 3,129 | 31,603 | 17,842 | 3,652 | 65,228 | ||||||||||
Roland Diggelmann, Member | 1,737 | 1,737 | 1,164 | 1,164 | ||||||||||||
Julie Tay, Member 3) | 1,258 | 1,258 | 685 | 685 | ||||||||||||
Ronald van der Vis, Member | 7,090 | 3,129 | 6,517 | 3,652 | ||||||||||||
Adrian Widmer, Member | 2,468 | 2,468 | 1,895 | 1,895 | ||||||||||||
Total (active members) | 109,685 | 29,148 | 31,603 | 103,776 | 30,328 | 65,228 | ||||||||||
Jinlong Wang, Member 4) | 11,163 | 3,652 | ||||||||||||||
Total (including former members) | 109,685 | 29,148 | 31,603 | 114,939 | 33,980 | 65,228 | ||||||||||
1)These shares are subject to a restriction period which varies from June 1, 2024 to June 1, 2029 depending on the grant date.
2)These shares are subject to a restriction period which varies from June 1, 2023 to June 1, 2028 depending on the grant date.
3)New member of the Board of Directors since June 2022.
4)Member of the Board of Directors until June 2023.
For further details see also Note 7.4 in the consolidated financial statements.
The shareholding requirements set by the share ownership guidelines are entirely met by all members of the Board of Directors.
The tables in this section are audited by the external auditor.
The following tables show the equity of individual members of the Management Board and persons closely linked to them.
31.03.2024 | 31.03.2023 | |||||||||||||||
Shares 1) | PSUs | RSUs | Options | Shares 1) | PSUs | RSUs | Options | |||||||||
Arnd Kaldowski Chief Executive Officer | 20,515 | 11,152 | 227,399 | 19,191 | 10,527 | 211,720 | ||||||||||
Birgit Conix Chief Financial Officer | 195 | 2,388 | 9,873 | 195 | 2,388 | 10,378 | ||||||||||
Ludger Althoff Group Vice President Operations | 2,156 | 3,482 | 26,048 | 1,447 | 3,058 | 264 | 21,771 | |||||||||
Vicky Carr-Brendel Group Vice President Cochlear Implants and President of Advanced Bionics | 1,057 | 2,394 | 20,837 2) | 628 | 3,068 | 237 | 21,138 2) | |||||||||
Christophe Fond Group Vice President Audiological Care | 2,100 | 2,975 | 33,476 | 3,855 | 162 | 40,779 | ||||||||||
Martin Grieder Group Vice President Consumer Hearing | 1,418 | 3,916 | 42,631 | 1,370 | 3,521 | 158 | 50,989 | |||||||||
Katya Kruglova 3) Group Vice President Corporate Human Resources & Communications | 88 | 1,822 | 7,641 | |||||||||||||
Robert (Rob) Woolley 4) GVP Hearing Instruments | 2,392 | 1,013 | 15,989 | 842 | 1,350 | 9,730 | ||||||||||
Total (active members) | 27,529 | 30,521 | 1,013 | 383,894 | 22,831 | 27,259 | 2,171 | 366,505 | ||||||||
Claudio Bartesaghi 5) | 2,047 | 1,926 | 12,435 | |||||||||||||
Total (including former members) | 27,529 | 30,521 | 1,013 | 383,894 | 24,878 | 29,185 | 2,171 | 378,940 | ||||||||
1)Shares are dividend entitled with full voting rights.
2)SARs were granted instead of options (SARs grant the right to participate in the appreciation of Sonova shares without issuance of shares).
3)Member of the Management Board since May 2023.
4)Member of the Management Board since April 2022.
5)Member of the Management Board until May 2023.
For further details see also Note 7.4 in the consolidated financial statements.
As of March 31, 2024 the shareholding requirements set by the share ownership guideline are met by all members of the Management Board except for two member, who re-committed to meet the requirements by June 30, 2024.
The following table shows the shareholding requirements relative to the fixed base salary and the indicative actual shareholdings.
Base salary | Share requirements 1) | Actual shares 2) | Fulfillment of share ownership guidelines | Share ownership ratio to base salary | ||||||
in CHF | in CHF | in CHF | in % | ratio | ||||||
Arnd Kaldowski, CEO | 900,000 | 1,000,000 | 5,356,467 | 536 | 6.0 | |||||
Other members of the MB 3) | 438,856 | 200,000 | 439,366 | 220 | 1.0 | |||||
1)Share requirements to be achieved for the CEO as of December 31, 2017 and for all other members of the MB after 38 months.
2)Calculated with Sonova closing share price of March 28, 2024.
3)Average of other members of the MB with shareholding requirements (excluding members of the MB that are still in build-up phase for shareholding requirements).
The calculation of fulfillment and the ratio to base salary of the share ownership shown above are included for illustration purposes only.
The following table shows a detailed breakdown of the outstanding options of the members of the Management Board.
31.03.2024 | ||||||||||||||||
Options EEAP 24 1) | Options EEAP 23 2) | Options EEAP 22 3) | Options EEAP 21 4) | Options EEAP 20 5) | Options EEAP 19 6) | Options EEAP 18 7) | Total options | |||||||||
Arnd Kaldowski | 18,400 | 21,832 | 15,037 | 25,454 | 28,119 | 32,901 | 85,656 8) | 227,399 | ||||||||
Other members of the MB | 20,531 | 27,048 9) | 21,208 9) | 20,837 9) | 24,712 9) | 27,438 9) | 14,721 | 156,495 9) | ||||||||
Total | 38,931 | 48,880 | 36,245 | 46,291 | 52,831 | 60,339 | 100,377 | 383,894 | ||||||||
1)Exercise price CHF 279.10, vesting period 1.2.2024–1.6.2028 whereas one tranche being vested each year, end of restriction period 31.1.2029, exercise period 1.2.2029–31.1.2034.
2)Exercise price CHF 233.40, vesting period 1.2.2023–1.6.2027 whereas one tranche being vested each year, end of restriction period 31.1.2028, exercise period 1.2.2028–31.1.2033 and for one member exercise price CHF 278.20, vesting period 2.5.2023–1.6.2027 whereas one tranche being vested each year, end of restriction period 31.1.2028, exercise period 1.2.2028–31.1.2033.
3)Exercise price CHF 333.60, vesting period 1.2.2022–1.6.2026 whereas one tranche being vested each year, end of restriction period 31.1.2027, exercise period 1.2.2027–31.1.2032.
4)Exercise price CHF 218.70, vesting period 1.2.2021–1.6.2025 whereas one tranche being vested each year, end of restriction period 31.1.2026, exercise period 1.2.2026–31.1.2031.
5)Exercise price CHF 241.80, vesting period 1.2.2020-1.6.2024 whereas one tranche being vested each year, end of restriction period 31.1.2025, exercise period 1.2.2025–31.1.2030.
6)Exercise price CHF 182.40, vesting period 1.2.2019-1.6.2023 whereas one tranche being vested each year, exercise period 1.6.2020-31.1.2029.
7)Exercise price CHF 147.85, vesting period 1.2.2018-1.6.2022 whereas one tranche being vested each year, exercise period 1.6.2019-31.1.2028.
8)Includes the one-time, non-recurring performance option grant (46,528 options); exercise price of CHF 147.85, vesting period of 1.2.2018 – 1.4.2025, exercise period 1.4.2025 – 30.9.2027.
9)For one member SARs were granted instead of options (SARs grant the right to participate in the appreciation of Sonova shares without issuance of shares).
31.03.2023 | ||||||||||||||||
Options EEAP 23 1) | Options EEAP 22 2) | Options EEAP 21 3) | Options EEAP 20 4) | Options EEAP 19 5) | Options EEAP 18 6) | Options EEAP 17 7) | Total options | |||||||||
Arnd Kaldowski | 21,832 | 16,871 | 25,454 | 28,119 | 32,901 | 86,543 8) | 211,720 | |||||||||
Other Members MB | 24,180 9) | 23,027 9) | 20,837 9) | 24,712 9) | 27,438 9) | 18,721 | 15,870 | 154,785 9) | ||||||||
Total (active members) | 46,012 | 39,898 | 46,291 | 52,831 | 60,339 | 105,264 | 15,870 | 366,505 | ||||||||
Former Member | 2,355 | 4,210 | 4,649 | 1,221 | 12,435 | |||||||||||
Total (including former members) | 46,012 | 42,253 | 50,501 | 57,480 | 61,560 | 105,264 | 15,870 | 378,940 | ||||||||
1)Exercise price CHF 233.40, vesting period 1.2.2023–1.6.2027 whereas one tranche being vested each year, end of restriction period 31.1.2028, exercise period 1.2.2028–31.1.2033.
2)Exercise price CHF 333.60, vesting period 1.2.2022–1.6.2026 whereas one tranche being vested each year, end of restriction period 31.1.2027, exercise period 1.2.2027–31.1.2032.
3)Exercise price CHF 218.70, vesting period 1.2.2021–1.6.2025 whereas one tranche being vested each year, end of restriction period 31.1.2026, exercise period 1.2.2026–31.1.2031.
4)Exercise price CHF 241.80, vesting period 1.2.2020-1.6.2024 whereas one tranche being vested each year, end of restriction period 31.1.2025, exercise period 1.2.2025–31.1.2030.
5)Exercise price CHF 182.40, vesting period 1.2.2019-1.6.2023 whereas one tranche being vested each year, exercise period 1.6.2020-31.1.2029.
6)Exercise price CHF 147.85, vesting period 1.2.2018-1.6.2022 whereas one tranche being vested each year, exercise period 1.6.2019-31.1.2028.
7)Exercise price CHF 130.00, vesting period 1.2.2017-1.6.2021 whereas one tranche being vested each year, exercise period 1.6.2018-31.1.2024.
8)Includes the one-time, non-recurring performance option grant (47,415 options); exercise price of CHF 147.85, vesting period of 1.2.2018 – 1.4.2025, exercise period 1.4.2025 – 30.9.2027.
9)For one member SARs were granted instead of options (SARs grant the right to participate in the appreciation of Sonova shares without issuance of shares).
AC Audit Committee
AGM Annual General Shareholdersʼ Meeting
AHV Old Age and Survivorsʼ Insurance
ALV Unemployment Insurance
Articles of Association Articles of Association of Sonova Holding AG
ASP Average Sales Price
BoD Board of Directors
CEO Chief Executive Officer
CFO Chief Financial Officer
CHF Swiss Francs
EBITA Earnings Before Interest, Taxes and Amortization
EEAP Executive Equity Award Plan
EPS Earnings Per Share
ESG Environmental, Social and Governance
FCF Free Cash Flow
GVP Group Vice President
HRM Human Resource Management
KPIs Key Performance Indicators
MB Management Board
n.a. Not applicable
NCC Nomination and Compensation Committee
OPEX Operating Expenses
PSU Performance Share Unit
ROCE Return on Capital Employed
RSU Restricted Share Unit
rTSR relative Total Shareholder Return
SLI Swiss Leaders Index
SMI Swiss Market Index
Sonova Excellence Sonova Excellence System
VCC Variable Cash Compensation